References
- Kykalos S, Mathaiou S, Karayiannakis AJ, et al. Tissue expression of the proteins Fas and Fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer 2012;43:224--8
- Smith FJD. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003;4:347–64
- Morsi HM, Leers MP, Jäger W, et al. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium. Int J Gynecol Pathol 2000;19:118–26
- Kadyrov M, Kaufmann P, Huppertz B. Expression of a cytokeratin 18 neo-epitope is a specific marker for trophoblast apoptosis in human placenta. Placenta 2001;22:44–8
- ILoo DT. In situ detection of apoptosis by the TUNEL assay: an overview of techniques. Methods Mol Biol 2011;682:3–13
- Leers MP, Kölgen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitopc exposed during early apoptosis. J Pathol 1999;187:567–72
- Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003;199:221–8
- Backus HJ, Van Groeningen CJ, Vos W, et al. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 2002;55:206–11
- Sugita J, Ohtani H, Mizoi T, et al. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res 2002;93:320–8
- Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009;9:88
- Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751–6
- Koornstra JJ, De Jong S, Hollema H, et al. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 2003;45:37–53
- Bivén K, Erdal H, Hägg M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003;8:263–8
- Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004;214:1–9
- Debucquoy A, Goethals L, Libbrecht L, et al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis 2009;24:129–38
- Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002;80:131–7
- Koornstra JJ, Rijcken FE, de Jong S, et al. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 2004;44:9–17
- Houston A, O’Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004;4:321–6
- O'Connell J, Bennett MW, Nally K, et al. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 2000;910:178–95